BMS-191095, a cardioselective mitochondrial katp opener, inhibits human platelet aggregation by opening mitochondrial katp channels
Authors:
- 1 January 2005
- journal article
- research article
- Published by Springer Nature in Archives of Pharmacal Research
- Vol. 28 (1) , 61-67
Abstract
We evaluated the antiplatelet effects of two classes of ATP-sensitive potassium channel openers (KATP openers) on washed human platelets, and the study’s emphasis was on the role of mitochondrial KATP in platelet aggregation. Collagen-induced platelet aggregation was inhibited in a dose dependent manner by lemakalim and SKP-450, which are potent cardio-nonselective KATP openers, and also by cardioselective BMS-180448 and BMS-191095 (IC50: 1,130, >1,500, 305.3 and 63.9 μM, respectively), but a significantly greater potency was noted for the cardioselective KATP openers. The latter two KATP openers also inhibited platelet aggregation induced by thrombin, another important blood-borne platelet activator, with similar rank order of potency (IC50: 498.0 and 104.8 μM for BMS-180448 and BMS-191095, respectively). The inhibitory effects of BMS-191095 on collagen-induced platelet aggregation were significantly blocked by a 30-min pretreatment of platelets with glyburide (1 μM) or sodium 5-hydroxydecanoate (5-HD, 100 μM), a nonselective and selective mitochondrial KATP antagonist, respectively, at similar magnitudes; this indicates the role of mitochondrial KATP in the antiplatelet activity of BMS-191095. However, glyburide and 5-HD had no effect when they were added to the platelet cuvette immediately prior to the addition of BMS-191095. These findings indicate that cardioselective mitochondrial KATP openers like BMS-191095 are able to exert cardioprotective effects in cardiac ischemia/reperfusion injury via dual mechanisms directed at the inhibition of platelet aggregation and the protection of cardiomyocytes, and both these mechanisms are mediated by mitochondrial KATP.Keywords
This publication has 34 references indexed in Scilit:
- Pharmacologic Profile of the Selective Mitochondrial‐KATPOpener BMS‐191095 for Treatment of Acute Myocardial IschemiaCardiovascular Drug Reviews, 2002
- In Vivo Characterization of the Mitochondrial Selective KATP Opener (3 R)-trans-4-((4-Chlorophenyl)-N-(1 H-imidazol-2-ylmethyl)dimethyl-2 H-1-benzopyran-6-carbonitril Monohydrochloride (BMS-191095): Cardioprotective, Hemodynamic, and Electrophysiological EffectsThe Journal of Pharmacology and Experimental Therapeutics, 2002
- Abnormal function of potassium channels in platelets of patients with Alzheimer's diseaseThe Lancet, 1998
- Pharmacological Evidence of Calcium-Activated and Voltage-Gated Potassium Channels in Human PlateletsClinical Science, 1997
- The Mitochondrial K Channel as a Receptor for Potassium Channel OpenersJournal of Biological Chemistry, 1996
- Hemodynamic and Cardiac Effects of BMS-180448, a Novel KATP Opener, in Anesthetized Dogs and Isolated Rat HeartsPharmacology, 1996
- Glyburide-reversible cardioprotective effect of BMS-180448 is independent of action potential shorteningCardiovascular Research, 1995
- Potassium channels and preconditioning of isolated rabbit cardiomyocytes: Effects of glyburide and pinacidilJournal of Molecular and Cellular Cardiology, 1995
- Cardioselective anti-ischemic ATP-sensitive potassium channel openersJournal of Medicinal Chemistry, 1993
- The efflux of86Rb and [3H]5-HT from human platelets during continuous perfusion: Effects of potassium-induced membrane depolarization and thrombin stimulationActa Physiologica Scandinavica, 1991